20/20 Biolabs, Inc. · NASDAQ:AIDX
20/20 Biolabs — Investor Presentation (September 2026)
23 slides from 20/20 Biolabs's investor presentation, Sep 2, 2026
Slide 1: Investor Webinar September 2, 2026
Investor Webinar NASDAQ: AIDX September 2, 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements and information relating to, among other things, the Company, its business plan and strategy, and its industry. These statements reflect management's current views with respect to future events based on information c
Slide 3: Today's Presentation
Today's Presentation • Overview of AIDX (5-minutes; for 1st time attendees) • Updates & Progress since August 5 Webinar (25 minutes) o Presentation of OneTest Ultimate @ Next Gen Diagnostics Summit o Advancing our FDA strategy & Preliminary meetings w/ FDA leadership o Lighthouse Lab Webinar o Comme
Slide 4: Congress Creates a Pathway for Medicare Reimbursement for Multi-Cancer Tests by 2028
Congress Creates a Pathway for Medicare Reimbursement for Multi- Cancer Tests by 2028 • Establishes the first statutory pathway for Medicare coverage of MCED blood tests • CMS authority to reimburse MCEDs beginning in 2028 • Applies to FDA-approved MCED tests deemed clinically appropriate by CMS • I
Slide 5: Grail's NHS-Galleri Data at ASCO Signals Trouble for Medicare Coverage of Galleri
Grail's NHS-Galleri Data at ASCO Signals Trouble for Medicare Coverage of Galleri • Primary endpoint missed — no drop in combined Stage III/IV cancers overall • Stage I–II diagnoses rose just 16% when added to standard screening — unlikely to translate into a meaningful mortality benefit • ctDNA mis
Slide 6: OneTest for Medicare: Biomarker Tracking + Machine Learning + Anti-Inflammatory Diet
OneTest for Medicare: Biomarker Tracking + Machine Learning + Anti-Inflammatory Diet Biomarker Panel: 12 Markers Cancer protein tumor markers (PTMs) • AFP — liver, testicular, ovarian • CEA — lung, pancreatic, GI • CA 19-9 — pancreatic, liver, GI • CA 125 — ovarian, lung • CYFRA 21-1 — lung, head/ne
Slide 7: OneTest Advantages Over ctDNA — Our "Straight A's"
OneTest Advantages Over ctDNA — Our "Straight A's" • Accuracy for Earlier Stage Cancers • Affordability • Acceleration over Time • Aggregates Data from Multiple Sources • Access at Home & Workplaces • AI Compatible for Consumers & Clinicians
Slide 8: At Home Capillary Collection Now Makes Quarterly Testing Practical
8 At Home Capillary Collection Now Makes Quarterly Testing Practical & Velocity Algorithms Impactful
Slide 9: M&A Strategy
9 Expect to "bolt-on" or acquire other companies that are vertically or horizontally integrated with 20/20 (e.g., suppliers, distributors, or related products) M&A Strategy Desired Attributes for Acquired Companies • Health & wellness customer base overlaps with those of 20/20 - Early Cancer Detecti
Slide 10: How Cologuard's 2014 Medicare Coverage Ignited Exponential Revenue Growth
10 How Cologuard's 2014 Medicare Coverage Ignited Exponential Revenue Growth 4 4 2 39 99 266 0 50 100 150 200 250 300 2012 2013 2014 2015 2016 2017 Annual Revenue ($M) ← Medicare Coverage October 2014 FDA Approval Aug 11, 2014 — First stool DNA test approved Medicare NCD Issued Oct 9, 2014 — Coverag
Slide 11: Aligning MCED with MAHA
Aligning MCED with MAHA Combining Earlier Detection with Prevention through Anti- Inflammatory Lifestyle Interventions to Amplify and Accelerate Demonstrated Mortality Reductions Jonathan Cohen, CEO, 20/20 Biolabs Next Generation Diagnostics Summit · Washington, D.C. August 26, 2026 20/20 Biolabs ·
Slide 12: Mortality proof takes years—not months
20/20 Biolabs · Next Generation Diagnostics Summit · Washington, D.C. · August 2026 2 Mortality proof takes years—not months Time to the first randomized evidence of cancer-specific mortality reduction P PSA Prostate screening EARLY 1990s 2009 9 years median follow-up at first positive ERSPC mortali
Slide 13: MAHA reframed the national question
MAHA reframed the national question The federal chronic-disease agenda names root causes — poor nutrition, ultra- processed food, physical inactivity, environmental exposure, chronic stress — and directs research and payment toward prevention. Every one of those root causes is also a driver of chron
Slide 14: DII Tracks Mortality Risk in Both Directions
CLINICAL EVIDENCE DII Tracks Mortality Risk in Both Directions Using the pooled dose-response estimate, lower (negative) Dll scores correspond to lower relative mortality risk, while higher Dll scores correspond to higher risk. [1] Illustrative dose-response curve: negative DIl = lower relative risk
Slide 15: The combined model beats either lever alone
The combined model beats either lever alone Modeled deaths avoided in a cohort of 100,000 adults tested yearly over seven years 0 38 52 104 0 20 40 60 80 100 120 Usual care Prevention only MCED only MCED + prevention Why they compound Prevention lowers incidence, so fewer positives arrive at a fixed
Slide 16: Modeled deaths avoided: PSA alone vs. PSA + Inflammatory Biomarkers & Algorithms
Modeled deaths avoided: PSA alone vs. PSA + Inflammatory Biomarkers & Algorithms Illustrative 23-year comparison for 10,000 men offered guideline-concordant PSA screening PSA SCREENING ALONE 22 deaths avoided Prostate-cancer deaths avoided per 10,000 men invited to screening over 23 years Long-term
Slide 17: Find it earlier. Prevent it beforehand.
Find it earlier. Prevent it beforehand. MCED without prevention treats cancer as inevitable. Prevention without detection asks the public to wait decades for proof. Together, they are the only combination that reduces mortality in this decade — and the federal agenda and the diagnostics industry are
Slide 18: FDA Engagement Update: Initial Leadership Discussions
2020 BIOLABS FDA Engagement Update: Initial Leadership Discussions August 25–26, 2026 | Washington, D.C. WHAT OCCURRED • Two in-person discussions with senior FDA personnel involved in in vitro diagnostics and MCED review • Discussions took place during the Next Generation Diagnostics Summit • Topic
Slide 19: Advancing the FDA Strategy: Planned Next Steps
2020 BIOLABS Advancing the FDA Strategy: Planned Next Steps A disciplined sequence from preliminary engagement to formal agency interaction 1 STRUCTURE THE EVIDENCE Refine the proposed evidence package, including internal studies, external datasets and a prospectively planned real- world evidence pr
Slide 20: A National Laboratory Network for MCED Commercialization
A National Laboratory Network for MCED Commercialization A Distribution / Franchise Model for Protein Tumor Marker based Multi- Cancer Early Detection Blood Tests Jon Harol, CEO, Lighthouse Labs Jonathan Cohen, CEO, 20/20 Biolabs Mao Mao, CEO, SeekIn Lighthouse Laboratories Webinar September 2, 2026
Slide 21: Sales Update
Sales Update • Q2 2026 produced our best quarterly cancer testing revenue to date. • 47% increase in revenue year-over-year • 29 Orders from New Accounts o Including Occupational and Preventive Health Companies, Fire Departments, and Primary Care Physicians • Maryland Firefighter Cancer Screening Pr
Slide 22: Sales Update • Highlights
Sales Update • Highlights o New Occupational Health Partners starting to deliver with orders o 1 in North Carolina o 2 in Texas o Expanding our ability to access fire departments, but also other industries, i.e. the energy sector o Expanding work with non-profit organizations o TF – 7294 Foundation
Slide 23: Key Takeaway
Key Takeaway: AIDX has the upside potential of a biopharmaceutical company (in Phase II clinical trials) with the downside protection of an early revenue stage Dx or medtech company Jonathan Cohen CEO 240-453-6343 Investors@2020Biolabs.com NASDAQ: AIDX 2020biolabs.com
20/20 Biolabs — Investor Presentation (September 2026) on 6ix